Q32 Bio Inc.

Q32 Bio Inc. is a clinical-stage biotechnology company dedicated to developing targeted immune therapeutics that rebalance the immune system. Their focus is on treating autoimmune and inflammatory diseases by targeting potent regulators of both the innate and adaptive immune systems. They are developing two primary programs: one focusing on the IL-7/TSLP receptor pathways, and the other on the complement system, both of which are believed to play crucial roles in immune dysregulation. Q32 Bio is committed to addressing the unmet needs of patients suffering from these conditions and improving their quality of life.

Q32 Bio is headquartered in Waltham, Massachusetts, and has a team of experienced scientists, immunologists, and drug developers. They are currently evaluating their lead product candidates, Bempikibart (ADX-914) and ADX-097, in clinical trials. Bempikibart is being tested for the treatment of atopic dermatitis and alopecia areata, while ADX-097 is being investigated for its potential in renal and other complement-mediated diseases. Q32 Bio's innovative approach and commitment to research have positioned them as a leading player in the field of targeted immune therapeutics.

Q32 Bio is a clinical stage biotechnology company dedicated to developing biologic therapeutics that target the innate and adaptive immune systems, aiming to rebalance immunity in autoimmune and inflammatory diseases. Their mission is to transform the lives of patients by developing novel therapies that address immune dysregulation and help patients regain control of their health.

Q32 Bio prioritizes a collaborative and supportive culture, emphasizing teamwork, innovation, and a dedication to improving patients' lives. The company fosters a sense of community through initiatives like their Q-Café and regular community service events, demonstrating a genuine care for both employees and the patient communities they serve. This commitment to collaboration and a shared purpose attracts individuals passionate about developing innovative treatments and creating a positive impact in the field of immunology.